Literature DB >> 18562979

IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy.

Carmina Montoliu1, Blanca Piedrafita, Miguel A Serra, Juan A del Olmo, Amparo Urios, Jose M Rodrigo, Vicente Felipo.   

Abstract

BACKGROUND AND AIMS: Patients with liver cirrhosis may present minimal hepatic encephalopathy (MHE) that can be unveiled using specific neuropsychologic examination. Evaluation of MHE in cirrhotic patients might have prognostic value. The psychometric HE score (PHES) has been recommended as the "gold standard" in the diagnosis of MHE. It has been proposed that critical flicker frequency (CFF) analysis would be useful for easier detection of MHE. It would also be useful to have some peripheral parameter that could reflect the presence of MHE. It has been recently proposed that inflammation-associated alterations and hyperammonemia may cooperate in the induction of hepatic encephalopathy. The aim of the present work was to assess whether there is a correlation between the alterations in parameters reflecting inflammation, hyperammonemia, and the presence of MHE.
METHODS: We have studied in 55 patients with liver cirrhosis and 26 controls the performance in the PHES battery and the CFF, ammonia, and some interleukins (ILs) as inflammatory markers.
RESULTS: IL-6 and IL-18 were significantly higher (2.5-fold and 2.2-fold, respectively) in patients with MHE than in those without MHE. There were significant correlations between IL-6 or IL-18 levels and PHES score and CFF. Moreover, all patients with MHE had IL-6 levels higher than 11 ng/mL, whereas all patients without MHE had IL-6 levels lower than 11 ng/mL.
CONCLUSIONS: Inflammatory alterations related with IL-6 and IL-18 may contribute to MHE. Serum concentration of IL-6 and IL-18 may be useful to discriminate cirrhotic patients with and without MHE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18562979     DOI: 10.1097/MCG.0b013e31815e7f58

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  64 in total

Review 1.  Advances in the evaluation and management of minimal hepatic encephalopathy.

Authors:  Jennifer Y Montgomery; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

Review 3.  Role of astrocytes in brain function and disease.

Authors:  Marta Sidoryk-Wegrzynowicz; Michal Wegrzynowicz; Eunsook Lee; Aaron B Bowman; Michael Aschner
Journal:  Toxicol Pathol       Date:  2010-11-12       Impact factor: 1.902

Review 4.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis.

Authors:  Cristina R Bosoi; Mariana M Oliveira; Rafael Ochoa-Sanchez; Mélanie Tremblay; Gabriella A Ten Have; Nicolaas E Deutz; Christopher F Rose; Chantal Bemeur
Journal:  Metab Brain Dis       Date:  2016-12-15       Impact factor: 3.584

Review 6.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

Review 7.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 8.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

9.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

10.  Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy.

Authors:  Emi Yoshimura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Naota Taura; Satoshi Miuma; Hidataka Shibata; Takuya Honda; Fuminao Takeshima; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.